FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2263302822> ?p ?o ?g. }

• W2263302822 endingPage "1340" @default.
• W2263302822 startingPage "1333" @default.
• W2263302822 abstract "Enhancer of zeste homolog 2 (EZH2) plays an important role in tumor development and progression by interacting with histone and nonhistone proteins. In the current study, we analyzed prevalence and prognostic impact of EZH2 in prostate cancer. EZH2 expression was analyzed by immunohistochemistry on a tissue microarray containing more than 12400 prostate cancer specimens. Results were compared to tumor phenotype, biochemical recurrence and molecular subtypes defined by ERG status as well as genomic deletions of 3p, 5q, 6q and PTEN. EZH2 immunostaining was detectable in 56.6% of 10168 interpretable cancers and considered strong in 1.1%, moderate in 12.2% and weak in 43.3% of cases. High EZH2 expression was strongly associated with high Gleason grade (P < 0.0001), advanced pathological tumor stage (P < 0.0001), positive nodal status (P < 0.0001), elevated preoperative PSA level (P = 0.0066), early PSA recurrence (P < 0.0001) and increased cell proliferation P < 0.0001). High-level EZH2 staining was also associated with TMPRSS2:ERG rearrangement and ERG expression in prostate cancers (P < 0.0001) and was linked to deletions of PTEN, 6q15, 5q21 and 3p13 (P < 0.0001 each) particularly in ERG-negative cancers. The prognostic impact of EZH2 was independent of established pre- and postoperatively assessed clinicopathological parameters. EZH2 has strong prognostic impact in prostate cancer and might contribute to the development of a fraction of genetically instable and particularly aggressive prostate cancers. EZH2 analysis might therefore be of clinical value for risk stratification of prostate cancer." @default.
• W2263302822 created "2016-06-24" @default.
• W2263302822 creator A5004130130 @default.
• W2263302822 creator A5014573705 @default.
• W2263302822 creator A5021421424 @default.
• W2263302822 creator A5024801599 @default.
• W2263302822 creator A5049914905 @default.
• W2263302822 creator A5053478291 @default.
• W2263302822 creator A5060519896 @default.
• W2263302822 creator A5065312050 @default.
• W2263302822 creator A5066959937 @default.
• W2263302822 creator A5067591715 @default.
• W2263302822 creator A5072001228 @default.
• W2263302822 creator A5074342534 @default.
• W2263302822 creator A5083281543 @default.
• W2263302822 creator A5085320118 @default.
• W2263302822 creator A5086499788 @default.
• W2263302822 creator A5089661293 @default.
• W2263302822 creator A5090488652 @default.
• W2263302822 date "2015-09-21" @default.
• W2263302822 modified "2023-10-01" @default.
• W2263302822 title "Overexpression of enhancer of zeste homolog 2 (EZH2) characterizes an aggressive subset of prostate cancers and predicts patient prognosis independently from pre- and postoperatively assessed clinicopathological parameters" @default.
• W2263302822 cites W1519812131 @default.
• W2263302822 cites W1526884312 @default.
• W2263302822 cites W1797828706 @default.
• W2263302822 cites W1969485334 @default.
• W2263302822 cites W1969947723 @default.
• W2263302822 cites W1972149587 @default.
• W2263302822 cites W1972437632 @default.
• W2263302822 cites W1977090021 @default.
• W2263302822 cites W1977836335 @default.
• W2263302822 cites W1978761040 @default.
• W2263302822 cites W1982538300 @default.
• W2263302822 cites W1995652309 @default.
• W2263302822 cites W1996487270 @default.
• W2263302822 cites W1998566859 @default.
• W2263302822 cites W2004380688 @default.
• W2263302822 cites W2006974639 @default.
• W2263302822 cites W2011670486 @default.
• W2263302822 cites W2013149980 @default.
• W2263302822 cites W2015735594 @default.
• W2263302822 cites W2017329417 @default.
• W2263302822 cites W2019671588 @default.
• W2263302822 cites W2030246401 @default.
• W2263302822 cites W2048122601 @default.
• W2263302822 cites W2053823153 @default.
• W2263302822 cites W2054074987 @default.
• W2263302822 cites W2059058989 @default.
• W2263302822 cites W2067888597 @default.
• W2263302822 cites W2075188294 @default.
• W2263302822 cites W2079298594 @default.
• W2263302822 cites W2080571195 @default.
• W2263302822 cites W2087810003 @default.
• W2263302822 cites W2088231330 @default.
• W2263302822 cites W2093364695 @default.
• W2263302822 cites W2100365251 @default.
• W2263302822 cites W2102807020 @default.
• W2263302822 cites W2103226094 @default.
• W2263302822 cites W2107633226 @default.
• W2263302822 cites W2121158863 @default.
• W2263302822 cites W2125496315 @default.
• W2263302822 cites W2126701902 @default.
• W2263302822 cites W2137499286 @default.
• W2263302822 cites W2141077390 @default.
• W2263302822 cites W2142924577 @default.
• W2263302822 cites W2146191095 @default.
• W2263302822 cites W2160689782 @default.
• W2263302822 cites W2163913910 @default.
• W2263302822 cites W2172123503 @default.
• W2263302822 cites W2917837889 @default.
• W2263302822 doi "https://doi.org/10.1093/carcin/bgv137" @default.
• W2263302822 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/26392259" @default.
• W2263302822 hasPublicationYear "2015" @default.
• W2263302822 type Work @default.
• W2263302822 sameAs 2263302822 @default.
• W2263302822 citedByCount "40" @default.
• W2263302822 countsByYear W22633028222016 @default.
• W2263302822 countsByYear W22633028222017 @default.
• W2263302822 countsByYear W22633028222018 @default.
• W2263302822 countsByYear W22633028222019 @default.
• W2263302822 countsByYear W22633028222020 @default.
• W2263302822 countsByYear W22633028222021 @default.
• W2263302822 countsByYear W22633028222022 @default.
• W2263302822 countsByYear W22633028222023 @default.
• W2263302822 crossrefType "journal-article" @default.
• W2263302822 hasAuthorship W2263302822A5004130130 @default.
• W2263302822 hasAuthorship W2263302822A5014573705 @default.
• W2263302822 hasAuthorship W2263302822A5021421424 @default.
• W2263302822 hasAuthorship W2263302822A5024801599 @default.
• W2263302822 hasAuthorship W2263302822A5049914905 @default.
• W2263302822 hasAuthorship W2263302822A5053478291 @default.
• W2263302822 hasAuthorship W2263302822A5060519896 @default.
• W2263302822 hasAuthorship W2263302822A5065312050 @default.
• W2263302822 hasAuthorship W2263302822A5066959937 @default.
• W2263302822 hasAuthorship W2263302822A5067591715 @default.
• W2263302822 hasAuthorship W2263302822A5072001228 @default.
• W2263302822 hasAuthorship W2263302822A5074342534 @default.
• W2263302822 hasAuthorship W2263302822A5083281543 @default.

• next